Invention Grant
- Patent Title: Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction
-
Application No.: US16954095Application Date: 2018-12-17
-
Publication No.: US11542250B2Publication Date: 2023-01-03
- Inventor: Haitao Ji
- Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Applicant Address: US FL Tampa
- Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Current Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Current Assignee Address: US FL Tampa
- Agency: Meunier Carlin & Curfman LLC
- International Application: PCT/US2018/065963 WO 20181217
- International Announcement: WO2019/118961 WO 20190620
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D401/12
Abstract:
Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
Public/Granted literature
- US20210179583A1 INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION Public/Granted day:2021-06-17
Information query
